Quasi-Unicorn Ascends: Innbrea Unveils Provincial Research Institute to Accelerate Democratization of NK Cell Therapies

On January 26th, the Laba Festival, a day symbolizing renewal and new beginnings filled with hope, Imbioray (Hangzhou) Biomedical Co., Ltd., a "quasi-unicorn company" in the biopharmaceutical field, held a grand ceremony at its Hangzhou headquarters in the Guan Mountain Digital Intelligence Industrial Park to mark the "Unveiling Ceremony of the Zhejiang Provincial Enterprise Research Institute and the Inauguration Ceremony of Imbioray Medical Research Center." Leaders from government departments, including Chen Haijiang, former second-level inspector of the Zhejiang Provincial Department of Economy and Information Technology and deputy secretary of the Party Committee of industry associations; Chen Bin, first-level researcher of the Biomedical Division of the Hangzhou Municipal Bureau of Economy and Information Technology; Zeng Yang, deputy director of the Development and Reform Bureau of Binjiang District; Ding Wei, deputy director of the Economic and Information Bureau of Binjiang District; and Tan Jianjun, secretary of the Baima Lake Management Committee, as well as representatives from partner organizations, investment institutions, industry experts, Imbioray's Chairman Miao Zhenwei, Chief Financial Officer Yan Si'en, and core management team were present to witness this significant milestone for Imbioray.

At the event, Dr. Zhenwei Miao, Chairman of Imbioray, along with core team members, joined government leaders and industry partners to complete the unveiling and inauguration ceremony of the Imbioray Medical Research Center. This marks a new phase for the company in core technology research and development, achievement transformation, and industrial ecosystem construction, further solidifying Imbioray's global leading position in the off-the-shelf NK cell therapy sector.

Chen Bin, a first-class researcher from the Biomedical Department of Hangzhou Municipal Economic and Information Commission, stated in his speech: "The biotechnology industry is a strategic emerging industry that leads the future. Imbioray not only brings internationally leading cell therapy technology but also injects strong momentum into the cultivation and growth of our biotechnology industry cluster. The 'off-the-shelf' technology can significantly reduce treatment costs and time costs, allowing advanced cell therapy to move from 'niche' to 'universal benefit,' which fully aligns with our fundamental goal of developing the industry and benefiting the people."

At the unveiling ceremony, Chen Haijiang, former Second-Class Inspector of the Zhejiang Provincial Department of Economy and Information Technology and Deputy Secretary of the Party Committee of Industry Associations, and Ding Wei, Deputy Director of the Economic and Information Technology Bureau of Binjiang District, unveiled the plaque for Imbioray. This marked the company's official entry into the provincial-level R&D platform sequence. Relying on the provincial enterprise research institute platform, Imbioray will increase investment in basic research, attract top global talent and technical resources, and focus on breakthroughs in clinical development and research for immune cell combination therapies in disease areas with unmet clinical needs, building an innovative pipeline with global competitiveness.

At the ceremony, Dr. Miao Zhenwei, founder of Imbioray, highlighted the company's core technological advantages and future development strategies. Dr. Miao stated: "Since 2016, Imbioray has been fully committed to the field of NK cell therapy, an area where there were no precedents for successful drug development globally at that time. We have chosen a unique technical route – universal off-the-shelf NK cell therapy based on antibody-cell conjugation technology without viral vectors or gene editing, breaking through 'personalized customization' to achieve allogeneic use. Through scaled production, we have significantly reduced production preparation time and costs, greatly enhancing the accessibility of the technology, making it available and affordable for more people. In the future, Imbioray will strengthen clinical application and transformation in its new technology strategy, GCP new drug development, and 'Regulation 818' treatment technologies; and enhance R&D in clinical diagnostics, integrated pharmaceuticals and devices, anti-aging, and longevity drugs."

Currently, Imbioray has established four core products leading the industry, including off-the-shelf universal full-cycle product lines, autoimmune disease management product lines, full-stage cancer treatment solutions, and ADC+NK combination therapy. It has built a portfolio of 16 product pipelines covering multiple fields such as oncology, autoimmune diseases, and neurological disorders, initiating a new paradigm for NK cell therapy. Several products have entered Phase II clinical trials, demonstrating significant clinical application value and are expected to become the world's fastest-to-market innovative NK cell immunotherapy drugs.

During this strategic signing session, Imbioray and Beijing Deep Intelligent Yao officially reached an in-depth cooperation to jointly launch the ACC-NK Cell Therapy AI Intelligent Platform, injecting new momentum into technological breakthroughs in the field of immunotherapy. With its underlying technical accumulation and clinical transformation advantages in ACC-NK cell therapy, Imbioray collaborates with Deep Intelligent Yao, which relies on deep collaboration from top AI scientists worldwide along with senior experts in clinical, pharmaceutical, statistical, and regulatory fields. Through complementary technologies, both parties will accelerate the R&D cycle of ACC-NK therapy using AI technology.

This collaboration not only marks a new phase in the deep integration of AI technology and cellular immunotherapy but will also drive China's immunotherapy industry towards an upgrade in "precision, intelligence, and scale," bringing new hope to patients worldwide with unmet clinical needs.

Since its establishment, Imbioray has always regarded technological innovation as the core driving force for enterprise development. It has deeply cultivated in the field of NK cell therapy, focusing on breakthroughs in key core technologies such as NK cell domestication and cultivation. To meet clinical needs, it has built a comprehensive R&D system and clinical transformation pathway, establishing the application value of NK cell immunotherapy from "laboratory" to "bedside," solving multi-dimensional problems such as scientific effectiveness, clinical practicability, and social accessibility of NK cell immunotherapy.

Today's unveiling and move-in marks a new starting point for Imbioray's development. With technological innovation as the spear and industrial ecosystem as the shield, Imbioray will continue to push the boundaries of immunotherapy, bringing China-manufactured cell therapy technologies to the global stage.「The Light of Immunotherapy, Igniting New Hope for Life」The corporate philosophy is to illuminate the light of hope for more lives.

References:

1.https://mp.weixin.qq.com/s/JgunpQeUaewv6yRItYKKlg

ImbiorayShare”、“Like" and "In View"Give me a little recharge~"